Sales & Marketing News | pharmaphorum

News

Teva closes on $4.25bn deal to settle US-wide opioid litigat...

Teva Pharmaceutical says it has reached an agreement in principle to settle thousands of lawsuits accusing it of fuelling the opioid cr

News

Novartis takes aim at MS blockbuster Tysabri in US and Europ...

Regulators in the US and Europe have started to review Novartis' biosimilar version of Biogen's big-selling multiple sclerosis therapy Tysabri, which could reach the market next year.

News

Ginkgo buys Zymergen, but may shed drug discovery business

Zymergen's brand new plan to shift from a synthetic biology specialist to a drug discovery player has come to an early end, with the sale of the company to rival Ginkgo Bioworks.

News

Report finds UK risks falling behind rivals in life sciences

A just-published report on the UK's life sciences sector "ought to ring alarm bells across government," according to the Association of the British Pharmaceutical Industry (ABPI).<

News

Pfizer, Flynn fined £70m in resurrected epilepsy drug pricin...

Drugmakers Pfizer and Flynn Pharma have been fined £70 million ($84 million) by the UK Competition and Markets Authority (CMA) for overcharging the NHS for a widely-used epilepsy drug.

News

Roche CEO Severin Schwan to stand down after 14 years

Long-serving Roche chief executive Severin Schwan is stepping down, to be replaced next March by Thomas Schinecker, currently head of diagnostics at the Swiss group.

Teva closes on $4.25bn deal to settle US-wide opioid litigat...

Novartis takes aim at MS blockbuster Tysabri in US and Europ...

Ginkgo buys Zymergen, but may shed drug discovery business

Report finds UK risks falling behind rivals in life sciences

Pfizer, Flynn fined £70m in resurrected epilepsy drug pricin...

Roche CEO Severin Schwan to stand down after 14 years

Curium strikes $8bn deal to buy radiopharma rival Lantheus

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks